We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
25.93-1.34 (-4.91%)
At close: 04:00PM EDT
26.00 +0.07 (+0.27%)
After hours: 07:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
Previous Close27.27
Open26.99
Bid25.88 x 100
Ask26.01 x 100
Day's Range25.52 - 26.99
52 Week Range16.95 - 49.50
Volume1,299,267
Avg. Volume1,433,430
Market Cap2.117B
Beta (5Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-1.72
Earnings DateMay 08, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BEAM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Beam Therapeutics Inc.
    Analyst Report: CRISPR Therapeutics AGCrispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more